US20080241072A1 - Injectable void filler for soft tissue augmentation - Google Patents

Injectable void filler for soft tissue augmentation Download PDF

Info

Publication number
US20080241072A1
US20080241072A1 US12/054,990 US5499008A US2008241072A1 US 20080241072 A1 US20080241072 A1 US 20080241072A1 US 5499008 A US5499008 A US 5499008A US 2008241072 A1 US2008241072 A1 US 2008241072A1
Authority
US
United States
Prior art keywords
composition
agents
growth factor
plasticizer
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/054,990
Other languages
English (en)
Inventor
John J. Barry
Andreas Goessl
Heinz Gulle
Monika Mangold
Melitta Bilban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Priority to US12/054,990 priority Critical patent/US20080241072A1/en
Assigned to BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC. reassignment BAXTER HEALTHCARE S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BARRY, JOHN J., GOESSL, ANDREAS, BILBAN, MELITTA, GULLE, HEINZ, MANGOLD, MONIKA
Publication of US20080241072A1 publication Critical patent/US20080241072A1/en
Priority to US13/004,179 priority patent/US8377420B2/en
Priority to US13/738,400 priority patent/US9278160B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/225—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/502—Plasticizers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates generally to a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler.
  • the composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, superior to fibrin alone.
  • a variety of properties of said void filler can be effectively fine-tuned and altered by adjusting type and content of the particles as well as of the plasticizer contained in said void filler composition.
  • the fibrin composition of the present invention is a natural biomaterial. It is sterilizable and has low potential toxicity. It is easy to use and the rheology permit injection and where possible minimally invasive treatment. Alteration of the fibrin modifier (plasticizer) and or particulate component can allow for fine control of water uptake, swelling, degradation and release of bioactive molecules Furthermore the invention is fully resorbable. It has negligible exotherm and exhibits elastomeric mechanical behavior making it mechanically superior to fibrin alone.
  • the current invention seeks to extend the possible indications for the modified fibrin composition to include soft tissue indications. These include, but are not limited to, partial or full occlusion, augmentation, or filling soft tissue lumens and voids.
  • Lumens are taken to be the void space of tubular structures such as the vasculature, reproductive tract and gastrointestinal tract.
  • Voids are taken to include lesions, fissures, fistulae and diverticulae. These voids can be physiological or the result of infection, surgery, cyst, tumor removal, or traumatic injury or remodeling of the soft tissue.
  • FIG. 1 shows the release of fluorescein from fibrin clots without plasticizer and with either iodixanol or glycerol;
  • FIG. 2 shows the elasticity of the material and the varying the viscosity of the clots with different concentrations of contrast agents
  • FIG. 3 shows rheological data of compositions containing iodixanol as a plasticizer and increasing amounts of calcium salts.
  • the present invention relates generally to a multi-component system for an injectable soft tissue void filler composition, comprising:
  • the multi-component system for an injectable soft tissue void filler composition as defined above may further include any other component suitable for augmenting, strengthening, supporting, repairing, rebuilding, healing, occluding or filling a soft tissue, such as growth factors, chemotherapeutic or pharmacological agents, biologically active agents, hardening and/or adhesive compounds and mineral additives. These compounds may be contained in any of the components (a) to (d) of the multi-component system according to the present invention or may be comprised as extra components.
  • the fibrinogen component (a) of the multi-component system as defined above may further comprise one or more of extracellular matrix proteins, for example fibronectin, cellular associated proteins, other plasma derived proteins, for example blood clotting factor XIII (FXIII) and proteases, and protease inhibitors, and mixtures thereof.
  • the fibrinogen solution according to the present invention may also include any additive which is comprised in the state of the art for scientific and/or commercially available fibrinogen compositions, for example commercially available fibrinogen solutions.
  • fibrinogen includes not only fibrinogen per se, but also any clot forming substance, such as clot-forming derivatives of fibrinogen, such as “fibrin1”.
  • the amount of fibrinogen in component (a) of the multi-component system ranges for example from about 10 to about 200 mg/ml, such as from about 30 to about 150 mg/ml or from about 75 to about 115 mg/ml.
  • the thrombin component (b) of the multi-component system according to the present invention may further comprise additional compounds known in the art as well as one or both of the components (C) and (d), particularly the plasticizer component (c).
  • additional compounds known in the art as well as one or both of the components (C) and (d), particularly the plasticizer component (c).
  • the amount of thrombin in said thrombin component (b) is such that it is at least about 1 IU/ml in the final clotted composition such as about 30 IU/ml.
  • thrombin includes not only thrombin per se, but also any gelation inducing or clotting inducing agent for component (a), for example a physiologically acceptable alkaline buffer system.
  • plasticizer includes any suitable substance useful in modifying the properties of the final clotted composition, for example the viscosity, the elastomeric behaviour or the mechanical stability.
  • the plasticizer of the multi-component system as defined above has a low osmolality and allows fibrin assembly to occur at an appropriate extent.
  • the suitable plasticizer of the multicomponent system according to the present invention comprises at least one biodegradable, water soluble organic compound.
  • biodegradable, water soluble organic compound further includes all compounds which can be degraded in a biological environment and are at least sufficiently soluble in water, for example at temperatures in the range from about 10 to about 40° C.
  • biodegradable is also taken to include plasticizers which are not degraded but are bioeliminated for example via excretory pathways.
  • plasticizer of the multi-component system are selected from the group consisting of water-soluble contrast agents, polyethylene glycols, polyvalent alcohols such as glycerol (and derivates of), mono-, di-, tri- and polysaccharides and any combination thereof.
  • the suitable contrast agent of the multi-component system according to the present invention comprises at least one iodine containing organic compound.
  • organic compounds containing rare earth elements such as gadolinium can be used.
  • iodine containing organic compound includes all compounds which contain at least one iodine atom and/or iodine ion, bonded either physically or chemically, for example covalently or co-ordinatively.
  • iodine containing organic compound includes all compounds which contain at least one iodine atom and/or iodine ion, bonded either physically or chemically, for example covalently or co-ordinatively.
  • the same definition applies mutatis mutandis to the above-mentioned organic compound containing rare earth elements.
  • contrast agents examples include diatrizoate (meglumine), iodecol, iodixanol, iofratol, iogulamide, iohexol, iomeprol, iopamidol, iopromide, iotrol, ioversol, ioxaglate and metrizamide and mixtures thereof.
  • the amount of plasticizer in component (C) is such that it ranges from about 10 to about 80% w/v, such as from about 15 to about 60% w/v or from about 20 to about 40% w/v, in the final clotted composition.
  • particle includes any type of particle shape or form known in the art, for example spherical, angular or hollow.
  • the particles of the multi component system according to the present invention are biodegradable and/or biocompatible, non-toxic, non-watersoluble, inorganic and/or organic.
  • the particles comprise, for example, substances selected from the group consisting of calcium salts such as tricalcium phosphate, alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium phosphate, a polymorph of calcium phosphate, hydroxyapatite, calcium carbonate, calcium sulfate, polymeric compounds such as polyactide, polyglycolide, polycaprolactone, polytrimethylene carbonate, polyethylene glycol and random or ordered copolymers thereof, biodegradable or biocompatible glasses and ceramics and any combination thereof.
  • the particles are selected from the group consisting of tricalcium phosphate, alpha-tricalcium phosphate, betatricalcium phosphate and calcium phosphate and mixtures thereof, having a Ca/P ratio in the range of about 1.5 to about 2.
  • the particles of the present invention further include all commercially available compounds and/or mixtures known in the art to be used within the meaning of component (d).
  • said particles of the multi-component system of the present invention have a diameter of less than about 100 ⁇ m, for example less than about 50 ⁇ m.
  • the amount of the particles in component (d) ranges from about 1 to about 50% w/w, such as from about 10 to about 45% w/w or from about 30 to about 40% w/w in respect to the final clotted composition.
  • the amount of fibrinogen in component (a) of the multi-component system as defined above ranges from about 10 to about 200 mg/ml
  • the amount of thrombin in component (b) is such that it is at least about 1 IU/ml in the final clotted composition
  • the amount of plasticizer contained in component (c) is such that it ranges from about 10 to about 80% w/v in the final clotted composition
  • the amount of the particles in component (d) ranges from about 1 to about 50% w/w in respect to the final clotted composition.
  • the amount of fibrinogen in component (a) of the multi-component system as defined above ranges from about 75 to about 115 mg/ml
  • the amount of thrombin in component (b) is such that it ranges from about 25 IU/ml to about 50 IU/ml in the final clotted composition
  • the amount of plasticizer contained in component (C) is such that it ranges from about 30 to about 50% w/v in the final clotted composition
  • the amount of the particles in component (d) ranges from about 30 to about 40% w/w in respect to the final clotted composition.
  • the multi-component System for an injectable void filler composition comprises:
  • the multi-component system according to the present invention may contain the components either in form of a solution or of a dispersion or of a solid, for example as a lyophilisate, or any combination thereof. Further, the components in said multi-component system may be present in containers suitable for storage, transportation or use of said multi-component system.
  • the containers usable in the multi-component system according to the present invention are not limited in any way but include containers of any size, material or shape, for example vials or syringes.
  • components of said multi-component system may for example be contained in different containers or may be present in the same container in any combination, for example as a combination of components (b) and (c) in one container and of components (a) and (d) each in different containers.
  • the containers may for example contain one or more components as a solid, as well as a solvent separated from said components by a separation means in said container, wherein a solution of the respective one or more components can be prepared by breaking or removing said separation means.
  • the components (a) to (d) of the multi-component system of the present invention may be also present as a ready-to-use mixture.
  • kits comprising the multi-component system as defined above.
  • the kit may further comprise any additional compound usable in the multi-component system of the present invention, for example auxiliary agents, buffer salts or buffer solutions.
  • the kit as defined above may also contain means for mixing the components, for example syringes, Luer adapters, tubes, extra containers, etc.
  • Another aspect of the present invention relates to an injectable void filler composition, comprising:
  • the injectable soft tissue void filler composition is prepared from the multi-component system as defined above, for example by mixing the components of said multi-component system together and/or homogenizing said components.
  • the preparation of the injectable soft tissue void filler composition can be carried out at any suitable temperature, such as in the range from about 18 to about 37° C., for example at 25° C.
  • the injectable soft tissue void filler composition as defined above may further include any other component suitable for e.g. augmenting, strengthening, supporting, repairing, rebuilding, healing, occluding or filling a void, such as growth factors, chemotherapeutic or pharmacological agents, biologically active agents, hardening and/or adhesive compounds and mineral additives.
  • these compounds and/or agents can be chemically attached to the matrix, adsorbed on the particulate component, for example on calcium salt containing particles, trapped in the fibrin matrix or contained as a free molecule/drug particle, for example a powder.
  • the components (b) to (d) of the injectable soft tissue void filler composition according to the present invention are the same as defined for the multi-component system characterized above.
  • fibrin does not only refer to fully coagulated fibrinogen but further includes any mixture of fibrin and fibrinogen which may occur during formation of fibrin from fibrinogen using thrombin and, thus, includes any ratio of fibrinogen/fibrin and any grade of gelation and/or clotting conceivable as long as it has no negative impact on the final composition injected into the void.
  • the fibrin component (a) of the injectable void filler composition of the present invention further includes fibrin with only a small amount of fibrinogen or without any fibrinogen left in said fibrin.
  • the term “fibrin” further includes any partly or fully gelled or clotted form of component (a) as defined above.
  • the amount of fibrin in said fibrin component (a) of the injectable void filler composition as defined above ranges from about 5 to about 100 mg/ml, such as from about 15 to 65 mg/ml or from about 30 to 65 mg/ml in the final clotted composition.
  • the amount of fibrin in said fibrin component (a) of the injectable void filler composition of the present invention ranges from about 5 to about 100 mg/ml in the final clotted composition
  • the amount of thrombin in component (b) is at least about 1 IU/ml in the final clotted composition
  • the amount of plasticizer contained in component (c) ranges from about 10 to about 80% w/v in the final clotted composition
  • the amount of particles in component (d) ranges from about 1 to about 50% w/w in respect to the final clotted composition.
  • the injectable void filler composition as defined above is in a gelled or clotted state and has a viscosity suitable for injecting into soft tissue void.
  • gelled means any state of elevated viscosity when compared to the initial state. This can be observed for example in the formation of fibrin from fibrinogen or in a finely dispersed system of at least one solid phase and at least one liquid phase, such as a colloid. Further, the term “gelled” includes all states of gelation known in the art.
  • lotted means, for example, a gel comprising fibrin and includes any kind of coagulation state known in the art.
  • Fibrin sealant solution Freeze dried fibrinogen powder reconstituted with, aprotinin solution to a total clottable protein concentration of 91 mg/ml.
  • Iodixanol 5-[acetyl-[3-[acetyl-[3,5-bis(2,3-dihydroxy- propylcarbamoyl)-2,4,6-triiodo-phenyl]- amino]-2-hydroxy-propyl]-amino]-N, N′- bis(2,3-dihydroxypropyl)-2,4,6-triiodo- benzene-1,3-dicarboxamide
  • Iohexol 5-(acetyl-(2,3-dihydroxl-propyl)-amino)-N,N′- bis(2,3-dihydroxypropyl)-2,4,6-triiodo-benzene- 1,3-dicarboxamide Fluorescein 2-(6-hydroxy-3-oxo-x
  • Thrombin 500 IU/ml Freeze dried thrombin powder reconstituted with 5 ml of thrombin buffer, to a concentration of 500 IU/ml.
  • the composition is intended for injection into soft tissue voids where filling and local drug delivery is a requirement.
  • An example of such a requisite would be in the treatment of fistulae where the void could be filled with an antibiotic releasing material.
  • the fibrin functions as a biological matrix allowing fibroblast attachment/infiltration and natural healing to occur (Brown et al 1993).
  • a contrast agent as the plasticizer allows visualization and control of the application.
  • antibiotic is meant to describe any antimicrobial agent that can produce a desired therapeutic effect. It includes the “classical” antibiotics from the groups aminoglycosides/carbacephems/carbapenems/cephalosporins/glycopeptides/marolides/monobactams/penicillins/polypeptides/sulfonamides and tetracylides (soluble in water or organic solvents) and newly identified antimicrobial agents such as particulate/colloidal silver or bismuth thiols.
  • fistulae in this context is taken to mean non-branched simple fistulae from the groups (but not limited to) anal fistulae, ano-rectal fistulae, arteriovenous fistulae, gastric fistulae, intestinal fistulae vaginal fistulae and broncho-oesophageal fistulae.
  • the “liquidity” of the composition for a period of time post-mixing may allow for better filling of more complex fistulae and increased success rates when treating them (when compared to normal fibrin). However further investigation is required to demonstrate this.
  • composition is injected as a liquid into a void (mould). After 1 hr the clotted compositions are transferred to a phosphate buffer saline solution and the fluorescein release measured.
  • Clots with glycerol A 40% plasticizer (glycerol) and 10 IU/ml thrombin solution is prepared in a thrombin dilution buffer (40 mM CaCl 2 in double distilled water). The solution is then homogenized. The solution is centrifuged to remove bubbles and sterilized by filtering through a 0.22 ⁇ m filter. The fibrinogen is mixed with thrombin/plasticizer in a 1:1 ratio (therefore the plasticizer concentration in the gelled clot is halved).
  • a 40% plasticizer (glycerol) and 10 IU/ml thrombin solution is prepared in a thrombin dilution buffer (40 mM CaCl 2 in double distilled water). The solution is then homogenized. The solution is centrifuged to remove bubbles and sterilized by filtering through a 0.22 ⁇ m filter. The fibrinogen is mixed with thrombin/plasticizer in a 1:1 ratio (therefore the plasticizer concentration in
  • the syringes containing the particles and the thrombin are connected via a Luer adapter and the thrombin/glycerol and particles homogenized by transferring the contents from syringe to syringe thoroughly.
  • the syringes containing the thrombin/glycerol/particles and the fibrinogen are connected via a Luer adapter and the contents homogenized.
  • the material remains liquid for approximately 1-1.5 minutes. During this time it can be injected into the defect or alternatively after a few minutes it can be delivered as a preformed gel.
  • Clots with iodixanol A 60% plasticizer (iodixanol) and 75 IU/ml thrombin solution is prepared in a thrombin dilution buffer (40 mM CaCl 2 in double distilled water). The solution is then homogenized. The solution is centrifuged to remove bubbles and sterilized by filtering through a 0.22 ⁇ m filter. The fibrinogen is mixed with thrombin/plasticizer in a 1:1 ratio (therefore the plasticizer concentration in the gelled clot is halved to 30%).
  • the syringes containing the particles and the thrombin are connected via a Luer adapter and the thrombin/CA and particles homogenized by transferring the contents from syringe to syringe thoroughly.
  • the syringes containing the thrombin/CA/particles and the fibrinogen are connected via a Luer adapter and the contents homogenized.
  • the material remains liquid for approximately 1 minute during this time it can be injected into the void or alternatively after a few minutes it can be delivered as a preformed gel.
  • the release of fluorescein from fibrin clots without plasticizer and with either iodixanol or glycerol can be taken from FIG. 1 .
  • the presence of the plasticizer in addition to changing the material properties alters the release of the candidate drug allowing a faster or a more prolonged/sustained release thereby allowing tailoring of the antimicrobial activity.
  • the fibrin/contrast agent/hydroxyapatite composition in this example can be used in place of collagen.
  • the composition is a soft elastic material better suited to the application than fibrin alone which would collapse in a similar fashion to collagen.
  • the fibrin/contrast agent/hydroxyapatite composition as defined above may also include any other component suitable for promoting natural tissue repair.
  • An example of such a molecule would be BMP-2.
  • a more extensive list of preferred growth factors/bioactive agents is detailed in the assigned U.S. Pat. No. 5,752,974, which is hereby incorporated by reference.
  • These compounds and/or agents can be chemically attached to the matrix, adsorbed on the particulate component, for example on calcium salt containing particles, trapped in the fibrin matrix or contained as a free molecule/drug particle, for example a powder.
  • Either an 80% or a 60% plasticizer (contrast agents iodixanol or iohexol) and a 75 IU/ml thrombin solution is prepared in a thrombin dilution buffer (40 mM CaCl 2 in double distilled water). The solution is then homogenised. The solution is centrifuged to remove bubbles and sterilized by filtering through a 0.22 ⁇ m filter. The fibrinogen is mixed with thrombin/contrast agent (CA) in a 1:1 ratio (therefore the plasticizer concentration in the gelled clot is halved to either 40 or 30%).
  • CA thrombin/contrast agent
  • the syringes containing the particles and the thrombin are connected via a Luer adapter and the thrombin/CA and particles homogenised by transferring the contents from syringe to syringe thoroughly.
  • the syringes containing the thrombin/CA/particles and the fibrinogen are connected via a Luer adapter and the contents homogenised.
  • the material remains liquid for approximately 1 minute during this time it can be injected into the defect or alternatively after a few minutes it can be delivered as a pre-formed gel.
  • compositions containing iodixanol as plasticizer and increasing amounts of calcium salts can be taken from FIG. 3 .
  • the composition can also be considered for use as a bulking agent for the cardiac sphincter in the treatment of Gastroesophageal Reflux Disease (GERD). While the treatment of GERD by this method has been found to be both feasible and safe (Zhi et al, 2005), it is possible that the presence of the x-ray opacifier can allow real time monitoring of the procedure and prevent injection transmurally through the wall of the esophagus. Complications such as this can be undetected at the time of the procedure and can lead to adverse effects.
  • GERD Gastroesophageal Reflux Disease
  • Occlusive devices are usually swellable materials. Some plasticizers confer this property on the invention composition. This is mainly due to the to the large plasticizer molecule being trapped in the composition and is unable to diffuse rapidly from the matrix. The net result is water uptake and swelling of the material to balance the osmotic forces.
  • Bone Plugs are well know in the art (U.S. Pat. No. 6,607,535, U.S. Pat. No. 5,861,043 which are herein incorporated by reference) and are used to restrict or prevent passage of bone cement into the medullary canal during hip replacement surgery.
  • U.S. Pat. No. 6,605,294 a rapidly hydrating hydrogel plug to occlude the femoral canal is introduced.
  • These hydrogel bone plugs are non-weight bearing but are expected to have significant benefits over non-degradable polyethylene plugs which remain as part of the implant.
  • An injectable fibrin composition containing iodixanol and tricalcium phosphate could also be used as a bone plug.
  • the composition in Example 2 is a rapidly hydrating matrix which swells on contact with fluid ensuring a tight fit between the invention composition and the femoral canal. Further advantages of using the invention composition is that it can be delivered minimally invasively and the delivery can be monitored due to the presence of the x-ray opacifier.
  • the injectable fibrin composition can be delivered via catheter for the prevention of pregnancy as described in the assigned U.S. Pat. No. 5,752,974.
  • the composition is injected such that the Fallopian tubes are filled/blocked.
  • the rapid hydration and swelling of the composition prevents the egg and or sperm from passing through or around the composition.
  • the fibrin would then function as a biological matrix allowing natural healing and fibrous scar tissue formation to occur (Brown et al 1993).
  • Bioactive molecules such as epidermal growth factor (EGF), transforming growth factor-alpha (TGF-[alpha]), transforming growth factor-beta (TGF-[beta]), human endothelial cell growth factor (ECGF), granulocyte macrophage colony stimulating factor (GM-CSF), bone morphogenetic protein (BMP), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), and/or platelet derived growth factor (PDGF)
  • EGF epidermal growth factor
  • TGF-[alpha] transforming growth factor-beta
  • ECGF transforming growth factor-beta
  • ECGF granulocyte macrophage colony stimulating factor
  • BMP bone morphogenetic protein
  • nerve growth factor NGF
  • VEGF vascular endothelial growth factor
  • FGF fibroblast growth factor
  • IGF insulin-like growth factor
  • PDGF platelet derived growth factor
  • the invention composition would be used to occlude and seal the gum line following dental surgery.
  • the composition is allowed to hydrate, swell and occlude providing a barrier against oral fluids/food materials and bacteria.
  • the absorbable composition will be degraded and replaced by natural tissue.
  • Vascular Occlusion can be used to limit or block blood flow in a blood vessel during a surgical technique or during the treatment of a pathophysiology. Examples of such pathophysiologies could be the limiting the blood flow to a tumor or an aneurysm.
  • the ability to deliver therapeutics agents along with the composition may further increase the suitability of the composition.
  • the blood flow to the weakened vessel could be restricted and a vasoactive molecule incorporated to allow remodeling of the vasculature around the weakened vessel.
  • the advantage of the invention composition is the swelling to ensure a good fit between the composition and the vessel. Alteration of the fibrin plasticizer can allow for fine control of water uptake, swelling, degradation and release of the therapeutic agents.
  • composition as a local drug delivery vehicle to treat diseased states such as cardiovascular disease, degenerative disc disease, bleeding peptic ulcers or the treatment of tumors.
  • the composition can be injected as a liquid, or a pre-formed gel, into/adjacent to or distant to the affected tissue.
  • the site specific delivery of the material would avoid the necessity of a high systemic dose to achieve efficacious dose levels in the tissue. Thus reducing the likelihood of toxicity.
  • the composition can functional mechanically in addition to releasing a therapeutic.
  • the invention composition can be injected adjacent to the ulcer where it would act mechanically to restrict blood flow to the area. This effect would be enhanced by the local delivery of the vasoconstrictor epinephrine.
  • the use of the formulation could be used to provide mechanical support in degenerative disc repair while simultaneously delivering anti-inflammatory or steroidal agents.
  • Cytotoxins and/or antibodies analgesics, anticoagulants, anti-inflammatory compounds, antimicrobial compositions, cytokines, drugs, growth factors, interferons, hormones, lipids, deminearlized bone or bone morphogenetic proteins, cartilage inducing factors, oligonucleotides, polymers, polysaccharides, polypeptides, protease inhibitors, vasoconstrictors vasodilators, vitamins and minerals (Pat. RE39192), the enhanced material properties of the current invention and the ability to tailor the release rates ( FIG. 1 .) make this more suitable as a local drug delivery vehicle.
  • Suitable classes of therapeutics include but are not limited to vasoactive agents, neuroactive agents, hormones, growth factors, cytokines, anesthetics and muscle relaxants, steroids, antibiotics, anticoagulants, anti-inflammatory agents, anti-proliferating agents, antiulcer agents, antivirals, immuno-modulating agents, cytotoxic agents, prophylactic agents, antigens and antibodies.
  • vasoactive agents include vasoactive agents, neuroactive agents, hormones, growth factors, cytokines, anesthetics and muscle relaxants, steroids, antibiotics, anticoagulants, anti-inflammatory agents, anti-proliferating agents, antiulcer agents, antivirals, immuno-modulating agents, cytotoxic agents, prophylactic agents, antigens and antibodies.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Composite Materials (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
US12/054,990 2007-03-26 2008-03-25 Injectable void filler for soft tissue augmentation Abandoned US20080241072A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/054,990 US20080241072A1 (en) 2007-03-26 2008-03-25 Injectable void filler for soft tissue augmentation
US13/004,179 US8377420B2 (en) 2007-03-26 2011-01-11 Injectable void filler for soft tissue augmentation
US13/738,400 US9278160B2 (en) 2007-03-26 2013-01-10 Injectable void filler for soft tissue augmentation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92004307P 2007-03-26 2007-03-26
US12/054,990 US20080241072A1 (en) 2007-03-26 2008-03-25 Injectable void filler for soft tissue augmentation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/004,179 Continuation US8377420B2 (en) 2007-03-26 2011-01-11 Injectable void filler for soft tissue augmentation

Publications (1)

Publication Number Publication Date
US20080241072A1 true US20080241072A1 (en) 2008-10-02

Family

ID=39560923

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/054,990 Abandoned US20080241072A1 (en) 2007-03-26 2008-03-25 Injectable void filler for soft tissue augmentation
US13/004,179 Active US8377420B2 (en) 2007-03-26 2011-01-11 Injectable void filler for soft tissue augmentation
US13/738,400 Active 2029-05-11 US9278160B2 (en) 2007-03-26 2013-01-10 Injectable void filler for soft tissue augmentation

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/004,179 Active US8377420B2 (en) 2007-03-26 2011-01-11 Injectable void filler for soft tissue augmentation
US13/738,400 Active 2029-05-11 US9278160B2 (en) 2007-03-26 2013-01-10 Injectable void filler for soft tissue augmentation

Country Status (17)

Country Link
US (3) US20080241072A1 (fr)
EP (1) EP2136852B1 (fr)
JP (2) JP5385257B2 (fr)
KR (1) KR101512863B1 (fr)
CN (1) CN101678151B (fr)
AT (1) ATE542552T1 (fr)
AU (1) AU2008230916B2 (fr)
BR (1) BRPI0809383B8 (fr)
CA (1) CA2682034C (fr)
CO (1) CO6241133A2 (fr)
DK (1) DK2136852T3 (fr)
ES (1) ES2381448T3 (fr)
HR (1) HRP20120092T1 (fr)
MX (1) MX2009010387A (fr)
PL (1) PL2136852T3 (fr)
PT (1) PT2136852E (fr)
WO (1) WO2008118913A2 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070276505A1 (en) * 2006-05-26 2007-11-29 Baxter International Inc. Injectable bone void filler
US20070275028A1 (en) * 2006-05-26 2007-11-29 Baxter International Inc. Injectable fibrin composition for bone augmentation
US20100331254A1 (en) * 2007-12-26 2010-12-30 Metamorefix Pulverized fibrin clots and pharmaceutical compositions containing them
US20110117027A1 (en) * 2007-03-26 2011-05-19 Baxter Healthcare S.A. Injectable void filler for soft tissue augmentation
US20120070477A1 (en) * 2009-05-28 2012-03-22 Profibrix B.V. Dry powder fibrin sealant
US8703170B2 (en) 2010-04-07 2014-04-22 Baxter International Inc. Hemostatic sponge
US9333245B2 (en) 2012-03-12 2016-05-10 The Regents Of The University Of California Methods and compositions for treating wounds and reducing the risk of incisional hernias
US20190015457A1 (en) * 2011-03-10 2019-01-17 Lifecell Corporation Elastic tissue matrix derived hydrogel
CN110997021A (zh) * 2017-05-30 2020-04-10 爱可法Ip有限公司 包含聚(1,3-三亚甲基碳酸酯)的可再吸收可生物降解的医药和化妆品组合物
US10702584B2 (en) * 2010-06-28 2020-07-07 Bbs-Bioactive Bone Substitutes Oyj Method for preparing a bone protein preparation and a bone protein preparation
US20210038767A1 (en) * 2017-10-18 2021-02-11 Lifecell Corporation Adipose tissue products and methods of production
US11826488B2 (en) 2017-10-19 2023-11-28 Lifecell Corporation Flowable acellular tissue matrix products and methods of production

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143722B2 (en) 2006-10-05 2012-03-27 Flipchip International, Llc Wafer-level interconnect for high mechanical reliability applications
US8678008B2 (en) 2008-07-30 2014-03-25 Ethicon, Inc Methods and devices for forming an auxiliary airway for treating obstructive sleep apnea
US8556797B2 (en) 2008-07-31 2013-10-15 Ethicon, Inc. Magnetic implants for treating obstructive sleep apnea and methods therefor
US8413661B2 (en) 2008-08-14 2013-04-09 Ethicon, Inc. Methods and devices for treatment of obstructive sleep apnea
US8561616B2 (en) 2008-10-24 2013-10-22 Ethicon, Inc. Methods and devices for the indirect displacement of the hyoid bone for treating obstructive sleep apnea
US8561617B2 (en) 2008-10-30 2013-10-22 Ethicon, Inc. Implant systems and methods for treating obstructive sleep apnea
US8783258B2 (en) 2008-12-01 2014-07-22 Ethicon, Inc. Implant systems and methods for treating obstructive sleep apnea
US8800567B2 (en) 2008-12-01 2014-08-12 Ethicon, Inc. Implant systems and methods for treating obstructive sleep apnea
US8307831B2 (en) 2009-03-16 2012-11-13 Ethicon, Inc. Implant systems and methods for treating obstructive sleep apnea
US9326886B2 (en) 2009-10-29 2016-05-03 Ethicon, Inc. Fluid filled implants for treating obstructive sleep apnea
US9877862B2 (en) 2009-10-29 2018-01-30 Ethicon, Inc. Tongue suspension system with hyoid-extender for treating obstructive sleep apnea
US9974683B2 (en) 2009-10-30 2018-05-22 Ethicon, Inc. Flexible implants having internal volume shifting capabilities for treating obstructive sleep apnea
US8632488B2 (en) 2009-12-15 2014-01-21 Ethicon, Inc. Fluid filled implants for treating medical conditions
US8905033B2 (en) 2011-09-28 2014-12-09 Ethicon, Inc. Modular tissue securement systems
US9161855B2 (en) 2011-10-24 2015-10-20 Ethicon, Inc. Tissue supporting device and method
US8973582B2 (en) 2011-11-30 2015-03-10 Ethicon, Inc. Tongue suspension device and method
US10470760B2 (en) 2011-12-08 2019-11-12 Ethicon, Inc. Modified tissue securement fibers
US9173766B2 (en) 2012-06-01 2015-11-03 Ethicon, Inc. Systems and methods to treat upper pharyngeal airway of obstructive sleep apnea patients
ES2692290T3 (es) * 2012-10-18 2018-12-03 Mayo Foundation For Medical Education And Research Técnicas para el tratamiento de abscesos
US20160303281A1 (en) 2015-04-17 2016-10-20 Rochal Industries, Llc Composition and kits for pseudoplastic microgel matrices
WO2017079328A1 (fr) * 2015-11-02 2017-05-11 Nanofiber Solutions, Inc. Fibres électrofilées ayant des agents de contraste et leurs procédés de fabrication
JP2022513442A (ja) 2018-12-11 2022-02-08 ナノファイバー ソリューションズ、エルエルシー 電界紡糸繊維を使用した慢性創傷の治療方法
CN114409734B (zh) * 2022-01-25 2023-05-12 四川大学华西医院 一种可诱导局部麻醉药生物矿化的自组装短肽及其制得的长效局部麻醉和镇痛药物制剂
CN114573660B (zh) * 2022-03-15 2023-06-13 四川大学华西医院 一种自组装短肽及其诱导局部麻醉药生物矿化制得的长效局部麻醉和镇痛药物制剂

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5752974A (en) * 1995-12-18 1998-05-19 Collagen Corporation Injectable or implantable biomaterials for filling or blocking lumens and voids of the body
US5861043A (en) * 1996-02-26 1999-01-19 Sunmed Inc. Intramedullary bone plug
US6096309A (en) * 1997-06-18 2000-08-01 Cohesion Technologies, Inc. Compositions containing thrombin and microfibrillar nanometer collagen, and methods for preparation and use thereof
US20010016646A1 (en) * 1998-03-20 2001-08-23 David C. Rueger Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
US6605294B2 (en) * 1998-08-14 2003-08-12 Incept Llc Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels
US6607535B1 (en) * 1999-02-04 2003-08-19 Kwan-Ho Chan Universal bone cement plug and method of use
US20040068266A1 (en) * 2002-10-04 2004-04-08 Yves Delmotte Devices and methods for mixing and extruding medically useful compositions
US20050119746A1 (en) * 2001-12-20 2005-06-02 Lars Lidgren Bone mineral substitute
USRE39192E1 (en) * 1990-11-27 2006-07-18 American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0166263A1 (fr) 1984-05-31 1986-01-02 Green Cross Corporation Composition de remplissage pour défaut ou partie creuse dans un os, "kit" ou "set" pour la préparation de cette composition
US4696812A (en) * 1985-10-28 1987-09-29 Warner-Lambert Company Thrombin preparations
GB8916781D0 (en) * 1989-07-21 1989-09-06 Nycomed As Compositions
FR2715853B1 (fr) 1994-02-08 1996-04-26 Centre Nat Rech Scient Composition pour bio-matériau; procédé de préparation.
US6287341B1 (en) * 1995-05-19 2001-09-11 Etex Corporation Orthopedic and dental ceramic implants
US5702715A (en) * 1995-10-27 1997-12-30 Drying Technology Reinforced biological sealants
US7041641B2 (en) * 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
WO2000007639A1 (fr) 1998-08-07 2000-02-17 Tissue Engineering, Inc. Compositions precurseurs osseuses
DE19956503A1 (de) * 1999-11-24 2001-06-21 Universitaetsklinikum Freiburg Spritzbares Knochenersatzmaterial
SE517168C2 (sv) * 2000-07-17 2002-04-23 Bone Support Ab En komposition för ett injicerbart ersättningsmaterial för benmineral
US20050136038A1 (en) * 2001-10-02 2005-06-23 Isotis N.V. Injectable calcium salt bone filler comprising cells
WO2003053488A1 (fr) 2001-12-20 2003-07-03 Bone Support Ab Nouveau substitut mineral d'os
US7341716B2 (en) * 2002-04-12 2008-03-11 Boston Scientific Scimed, Inc. Occlusive composition
US20050220882A1 (en) 2004-03-04 2005-10-06 Wilson Pritchard Materials for medical implants and occlusive devices
US7621952B2 (en) * 2004-06-07 2009-11-24 Dfine, Inc. Implants and methods for treating bone
MX2007008319A (es) 2005-01-06 2007-10-04 Kuros Biosurgery Ag Matrices suplementadas para la reparacion de fracturas oseas.
WO2006073711A2 (fr) 2005-01-06 2006-07-13 Kuros Biosurgery Ag Traitement local des deficits osseux
JP5315233B2 (ja) * 2006-05-26 2013-10-16 バクスター・インターナショナル・インコーポレイテッド 注入可能な骨空隙充填剤
AU2007268175B2 (en) * 2006-05-26 2013-05-23 Baxter Healthcare S.A. Injectable fibrin composition for bone augmentation
CA2682034C (fr) * 2007-03-26 2015-01-27 Baxter International Inc. Composant injectable de comblement d'espace vide utilise pour augmenter le volume d'un tissu mou

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39192E1 (en) * 1990-11-27 2006-07-18 American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5752974A (en) * 1995-12-18 1998-05-19 Collagen Corporation Injectable or implantable biomaterials for filling or blocking lumens and voids of the body
US5861043A (en) * 1996-02-26 1999-01-19 Sunmed Inc. Intramedullary bone plug
US6096309A (en) * 1997-06-18 2000-08-01 Cohesion Technologies, Inc. Compositions containing thrombin and microfibrillar nanometer collagen, and methods for preparation and use thereof
US20010016646A1 (en) * 1998-03-20 2001-08-23 David C. Rueger Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
US6605294B2 (en) * 1998-08-14 2003-08-12 Incept Llc Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels
US6607535B1 (en) * 1999-02-04 2003-08-19 Kwan-Ho Chan Universal bone cement plug and method of use
US20050119746A1 (en) * 2001-12-20 2005-06-02 Lars Lidgren Bone mineral substitute
US20040068266A1 (en) * 2002-10-04 2004-04-08 Yves Delmotte Devices and methods for mixing and extruding medically useful compositions

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421302B2 (en) 2006-05-26 2016-08-23 Baxter International Inc. Injectable fibrin composition for bone augmentation
US20070275028A1 (en) * 2006-05-26 2007-11-29 Baxter International Inc. Injectable fibrin composition for bone augmentation
US20070276505A1 (en) * 2006-05-26 2007-11-29 Baxter International Inc. Injectable bone void filler
US9248215B2 (en) 2006-05-26 2016-02-02 Baxter International Inc. Injectable bone void filler
US9724449B2 (en) 2006-05-26 2017-08-08 Baxter International Inc. Injectable fibrin composition for bone augmentation
US20110117027A1 (en) * 2007-03-26 2011-05-19 Baxter Healthcare S.A. Injectable void filler for soft tissue augmentation
US8377420B2 (en) 2007-03-26 2013-02-19 Baxter International Inc. Injectable void filler for soft tissue augmentation
US9278160B2 (en) 2007-03-26 2016-03-08 Baxter International Inc. Injectable void filler for soft tissue augmentation
US20100331254A1 (en) * 2007-12-26 2010-12-30 Metamorefix Pulverized fibrin clots and pharmaceutical compositions containing them
US20120070477A1 (en) * 2009-05-28 2012-03-22 Profibrix B.V. Dry powder fibrin sealant
US9119897B2 (en) * 2009-05-28 2015-09-01 Profibrix B.V. Dry powder fibrin sealant
US8703170B2 (en) 2010-04-07 2014-04-22 Baxter International Inc. Hemostatic sponge
US9375505B2 (en) 2010-04-07 2016-06-28 Baxter International Inc. Hemostatic sponge
US10441674B2 (en) 2010-04-07 2019-10-15 Baxter International Inc. Hemostatic sponge
US11478566B2 (en) 2010-04-07 2022-10-25 Baxter International Inc. Hemostatic sponge
US10702584B2 (en) * 2010-06-28 2020-07-07 Bbs-Bioactive Bone Substitutes Oyj Method for preparing a bone protein preparation and a bone protein preparation
US11219665B2 (en) 2010-06-28 2022-01-11 Bbs-Bioactive Bone Substitutes Oyj Method for preparing a bone protein preparation and a bone protein preparation
US12097243B2 (en) 2010-06-28 2024-09-24 BBS—Bioactive Bone Substitutes OYJ Method for preparing a bone protein preparation and a bone protein preparation
US20190015457A1 (en) * 2011-03-10 2019-01-17 Lifecell Corporation Elastic tissue matrix derived hydrogel
US9333245B2 (en) 2012-03-12 2016-05-10 The Regents Of The University Of California Methods and compositions for treating wounds and reducing the risk of incisional hernias
CN110997021A (zh) * 2017-05-30 2020-04-10 爱可法Ip有限公司 包含聚(1,3-三亚甲基碳酸酯)的可再吸收可生物降解的医药和化妆品组合物
US11331411B2 (en) * 2017-05-30 2022-05-17 Aqpha Ip B.V. Resorbable biodegradable medical and cosmetic composition comprising poly(1,3-trimethylene carbonate)
US20210038767A1 (en) * 2017-10-18 2021-02-11 Lifecell Corporation Adipose tissue products and methods of production
US11826488B2 (en) 2017-10-19 2023-11-28 Lifecell Corporation Flowable acellular tissue matrix products and methods of production

Also Published As

Publication number Publication date
PT2136852E (pt) 2012-02-08
KR101512863B1 (ko) 2015-04-16
US9278160B2 (en) 2016-03-08
EP2136852B1 (fr) 2012-01-25
WO2008118913A2 (fr) 2008-10-02
DK2136852T3 (da) 2012-04-16
JP5385257B2 (ja) 2014-01-08
MX2009010387A (es) 2009-10-19
CN101678151A (zh) 2010-03-24
ATE542552T1 (de) 2012-02-15
KR20090122492A (ko) 2009-11-30
BRPI0809383B1 (pt) 2018-10-30
BRPI0809383B8 (pt) 2021-06-22
BRPI0809383A2 (pt) 2014-09-09
US20130209370A1 (en) 2013-08-15
AU2008230916A1 (en) 2008-10-02
EP2136852A2 (fr) 2009-12-30
WO2008118913A3 (fr) 2009-12-03
JP2010522617A (ja) 2010-07-08
ES2381448T3 (es) 2012-05-28
HRP20120092T1 (hr) 2012-02-29
CA2682034A1 (fr) 2008-10-02
AU2008230916B2 (en) 2013-10-03
US8377420B2 (en) 2013-02-19
CA2682034C (fr) 2015-01-27
PL2136852T3 (pl) 2012-07-31
US20110117027A1 (en) 2011-05-19
JP2013138947A (ja) 2013-07-18
CO6241133A2 (es) 2011-01-20
CN101678151B (zh) 2014-04-16

Similar Documents

Publication Publication Date Title
US8377420B2 (en) Injectable void filler for soft tissue augmentation
AU2007268175B2 (en) Injectable fibrin composition for bone augmentation
AU2007268174B2 (en) Injectable bone void filler
US20100284919A1 (en) Injectable Radio-Opaque Compositions for Tissue Augmentation
AU2014200027B2 (en) Injectable void filler for soft tissue augmentation

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAXTER INTERNATIONAL INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARRY, JOHN J.;GOESSL, ANDREAS;GULLE, HEINZ;AND OTHERS;REEL/FRAME:021038/0036;SIGNING DATES FROM 20080526 TO 20080602

Owner name: BAXTER HEALTHCARE S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BARRY, JOHN J.;GOESSL, ANDREAS;GULLE, HEINZ;AND OTHERS;REEL/FRAME:021038/0036;SIGNING DATES FROM 20080526 TO 20080602

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION